Drug
Ligufalimab clinical trials
Also written AK117.
- studies test it
- 15
- open now
- 7
- in phase 3
- 2
- first study started
- 2020
Keep track of what changes. Save the ligufalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 11
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 3
Akeso (11) · West China Hospital (1) · Akesobio Australia Pty Ltd (1) · Groupe Oncologie Radiotherapie Tete et Cou (1) · University of Texas Southwestern Medical Center (1)
Often tested with
Tested in the same studies.
Ivonescimab (3) · Cadonilimab (2) · Cetuximab (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Gemcitabine (1)
Studies
Open first, then newest update. How each study uses ligufalimab is read from its arms, and is right about nine times in ten.
Testing it · 15
- Study Comparing Ivonescimab Alone or Ivonescimab in Combination With Ligufalimab Versus Pembrolizumab for the Treatment of SCCHNRecruitingPhase 3Groupe Oncologie Radiotherapie Tete et CouNCT07264075Written as Ligufalimab
- A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic CancerRecruitingPhase 3AkesoNCT06953999Written as Ivonescimab, AK117, Albumin-bound Paclitaxel, Gemcitabine
- Ligufalimab and Cadonilimab in Advanced Liver CancersRecruitingPhase 2University of Texas Southwestern Medical CenterNCT06789848Written as Ligufalimab
- A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin LymphomaRecruitingPhase 1/2AkesoNCT06642792Written as AK117
- A Study of AK117 in Combination With Azacitidine in Patients With Myelodysplastic SyndromesRecruitingPhase 2AkesoNCT06196203Written as AK117
- A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid LeukemiaNot yet recruitingPhase 1/2AkesoNCT06387420Written as AK117
- Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction AdenocarcinomaRecruitingPhase 2AkesoNCT05960955Written as AK117
- AK117 (Anti-CD47 mAb) Plus Cetuximab as Second-Line Therapy in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedPhase 2West China HospitalNCT06508606Written as AK117 + Cetuximab
- A Study of AK117/AK112 in Metastatic Triple-Negative Breast CancerActive, not recruitingPhase 2AkesoNCT05227664Written as AK117
- A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsActive, not recruitingPhase 1/2AkesoNCT05229497Written as AK117
- A Study of AK112 With or Without AK117 in Metastatic Colorectal CancerActive, not recruitingPhase 2AkesoNCT05382442Written as AK117
- A Trial of AK117 (Anti-CD47) in Patients With Myelodysplastic SyndromeActive, not recruitingPhase 1/2AkesoNCT04900350Written as AK117
- A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid LeukemiaActive, not recruitingPhase 1/2AkesoNCT04980885Written as AK117
- A Phase 1 Dose Escalation and Expansion Study of AK117CompletedPhase 1AkesoNCT04728334Written as AK117
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedPhase 1Akesobio Australia Pty LtdNCT04349969Written as AK117
Given in every arm · 3 — ligufalimab is usual care beside what is tested
- A Study of Ivonescimab in First-Line ES-SCLCRecruitingPhase 2AkesoNCT07245446Written as AK117
- A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant TumorsCompletedPhase 1/2AkesoNCT05235542Written as AK117
- A Study of AK112 in Advanced Malignant TumorsCompletedPhase 1/2AkesoNCT05214482Written as AK117
Codes
What other systems call ligufalimab · ClinicalTrials.gg INT014347
- UNII (FDA) 1S4338NZB8LIGUFALIMABOne source FDA
- NCI Thesaurus C176868LigufalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 1S4338NZB8 | LIGUFALIMAB | One source FDA |
| NCI Thesaurus | C176868 | Ligufalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.